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Abstract 
Objective 
A meeting was organized to bring together multiple stakeholders involved in the testing 
and authorization of new medicines for juvenile idiopathic arthritis (JIA) to discuss 
current issues surrounding trials and access of new medicines for children and 
adolescents with JIA. 
 
Methods 
The Childhood Arthritis and Rheumatology Research Alliance (CARRA) invited 
regulatory agencies (Food and Drug Administration [FDA] and European Medicines 
Agency [EMA]), major pharmaceutical companies with JIA products approved or in 
development, patient and parent representatives, advocacy organization (Arthritis 




The participants highlighted current issues in clinical trials. As the pharmacologic 
armamentarium to treat inflammatory arthritis rapidly expands, registration trial designs 
to test medicines in JIA patients must adapt. Many methodologies used successfully in 
the recent past are no longer feasible. The pool of patients meeting entry criteria who 
are willing to participate is shrinking at the same time that the number of medicines that 
need testing is growing. Solutions included proposing innovative clinical trial methods to 
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Conclusion 
Ensuring new medicines are authorized in a timely manner to meet the needs of JIA 
patients worldwide is critical. Approaches should include: open dialogue between 
regulatory agencies, pharmaceutical companies and other stakeholders to develop and 
implement novel study designs; including patient and clinician perspectives to define 
meaningful trial outcomes; and changing existing study plans. 
 
Introduction 
The impact of new biologics and small molecule therapeutics on inflammatory arthritis in 
the last two decades is remarkable and continuing to grow. The legislative agenda set 
by the United States Government with Pediatric Study Plans (PSPs) (1) and European 
Commission and Parliament with Paediatric Investigation Plans (PIPs) ensures that 
drug development includes pediatric trials (2). Pediatric trials of new drugs, primarily led 
by the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Pediatric 
Rheumatology International Trials Organization (PRINTO), have caused a sea change, 
leading to marked improvement in the outcomes and quality of life of children and 
adolescents with juvenile idiopathic arthritis (JIA). Pharmaceutical companies continue 
to develop additional drugs in both established and new drug classes. To continue the 
exponential trajectory of treatment advances, innovative approaches to testing and 
authorizing medicines are sorely needed, as current approaches do not meet the needs 
of stakeholders, including patients, regulators, clinicians, investigators and industry. 
Efforts to define patient centered outcomes consistently highlight unmet needs in the 
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researchers, patient/parents, the Arthritis Foundation, industry and regulatory agencies 
(Food and Drug Administration [FDA] and European Medicines Agency [EMA]) was held 
to discuss current challenges and potential solutions. Topics included novel study 
designs for authorization, increasing and diversifying patients available for clinical trial 
participation, and improving communication and collaboration between regulators and 
other stakeholders. In this article, we outline key issues raised at the meeting and 
possible approaches to push the field further forward.  
 
There are now highly effective biologic therapeutics with FDA and EMA approval for the 
treatment of JIA, including etanercept, adalimumab, abatacept, tocilizumab, and 
canakinumab (in EU also golimumab and anakinra). In this environment, it is crucial to 
rethink how clinical trials are performed and what data are required for product 
registration depending on whether a new drug class, new preparation of a registered 
drug, or new molecule in a well-studied drug class is involved. Adding to the growing 
complexity of registering additional products is the limited pool of children available to 
participate in trials, considering that approximately 40-60% of children with JIA 
(depending on subtype) have clinically inactive disease (CID) on medication(s) at one or 
two year follow up making them ineligible for a clinical trial (unpublished data, CARRA 
Registry). Similar results have been observed in other longitudinal observational 
registries in other countries: 38% had CID at one year in the UK, and 45% in Canada (4, 
5). The multiple current PIPs/PSPs agreed upon for testing in enthesitis related arthritis 
require more than the eligible patients in Europe and North America to fulfill industry 
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continue to be an urgent needed. Data from the above registries indicate that half of 
children with JIA are clinically active despite treatment at 2 years and approximately 
25% of participants treated with investigational products in JIA trials fail to achieve 
modest ACR 30 trial response definitions (4). At a recent meeting of the Systemic JIA 
Foundation, researchers presented that 5-10% of SJIA patients are resistant to both IL1 
and IL6 blockade. Safety concerns are also an ongoing issue with currently available 
medical treatments. Clearly more and better products are needed. A one-day meeting of 
stakeholders was held on April 11, 2018 in Denver, Colorado. Rheumatologists, 
researchers, patient/parents, the Arthritis Foundation, industry and regulatory agencies 
(FDA and EMA) discussed the current state of JIA clinical trials, outcome measures, the 
role of registries, and new approaches for JIA clinical trials, as well as next steps. The 
meeting was an initial discussion to highlight current issues and provide a call to action.  
 
Current state of clinical trials in JIA 
Most available medications were authorized for JIA treatment based on pediatric 
placebo controlled randomized clinical trial (RCT) results including all subtypes of JIA. 
Currently, a growing number of products are being developed for specific JIA 
categories, all of which are rare diseases. Given the current number of efficacious drugs 
for JIA (4-6), the robust development pipeline, and a dwindling number of eligible JIA 
patients, continuing the current model for obtaining regulatory approval is not feasible. 
Future trials may be feasible only if they enroll patients without medication access, due 
to either socioeconomic restraints or lack of drug availability at a national level. This 
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part of the sponsors’ marketing plans, as well as issues with generalizability of results. 
Enrollment issues extend the length of placebo-controlled trials increasing expense and 
delaying availability of novel medicines. A current example is the tofacitinib trial, which 
has yet to complete enrollment for the systemic JIA cohort of the study after several 
years, potentially depriving all polyarticular and systemic JIA patients of access to a new 
class of oral treatment, if found to be safe and effective (ClinicalTrials.gov Identifier: 
NCT03000439)(7). 
 
The randomized placebo-controlled withdrawal clinical trial design (8) is a commonly 
used alternative to the standard RCT that limits placebo exposure (9). Although 
successfully used to obtain authorization of the early biologics, this trial design now has 
notable issues. In this trial design, all participants are initially treated with open label 
study medication, then only participants meeting the trial definition of response (usually 
the JIA ACR 30), are randomized to placebo or continued active treatment. The 
difference in the flare rate between the placebo and active treatment arms in the 
withdrawal phase is the primary outcome (10). There are several methodological issues 
with this design. The initial open label design makes the outcome in the resultant 
responder group difficult to interpret and generalize. Valuable information about non-
responders is lost because they are excluded from the study after the open label phase, 
making the actual clinical efficacy of the therapeutic agent difficult to interpret and 
making it difficult to power future studies. Since all participants receive study drug, only 
limited information is gleaned about relative safety.  Responders may experience 
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effect or durability of response to open label drug.  Fewer patients may flare for these 
reasons, decreasing observed differences between the two treatment groups and 
leading to the false conclusion that the drug is not effective. This scenario, coupled with 
the long half-life of golimumab, may have led to negative results from a randomized 
withdrawal trial conducted for children with JIA, depriving children in the U.S. the use of 
this long acting anti-tumor necrosis factor (TNF) agent (note: EMA approved golimumab 
for JIA anyway, concluding the benefit/risk ratio was positive despite the negative trial 
results) (11, 12). Additionally, withdrawing an efficacious medication is no longer 
acceptable to patients, families, and clinicians, considering the availability of other 
agents and concerns about possibly missing a window of opportunity when effective 
early treatment may result in long term remission.  
 
RCT will continue to play an important but selective role. The first of a new class of 
medicines certainly warrants a rigorous clinical trial. However, many drugs currently in 
development are similar, though not identical (i.e., “me-too” drugs) to registered 
medications. Placebo-controlled trials of each new drug class, as well as the plethora of 
“me-too” drugs such as many new JAK inhibitors, are creating unprecedented demand 
for JIA patients to enroll in clinical trials. Simply stated, the demand for JIA patients 
cannot be met if every new medicine is studied using a PRCT. Therefore, alternative 













This article is protected by copyright. All rights reserved. 
Outcome measures used in JIA clinical trials 
Meaningful study outcomes are of central importance to evaluate medication efficacy. 
Ideally, study outcomes support an efficient trial design, are clinically meaningful and 
enable timely  disclosure of trial results to regulatory agencies, providers, and 
patients/families (14). Improved study endpoints in JIA clinical trials could meet these 
requirements. Outcome assessment in JIA is challenging due to the need to measure 
both response and disease activity, the need for measures that function across 
research settings and study designs, and the lack of objective variables or accurate 
biomarkers (15).  
 
Most common JIA clinical trial outcomes are response to therapy, flare, disease activity, 
damage, and a range of patient-reported outcomes (PROs) (16). The JIA American 
College of Rheumatology (ACR) measure of response to treatment and flare are 
composite measures that are the standard for registration trials (17). However, although 
this response measure is familiar to investigators, it does not reflect disease activity 
level, making clinically useful interpretation challenging. Furthermore, with effective 
treatments available, the standard JIA ACR 30 (meaning 30% improvement from 
baseline) is no longer a satisfactory, meaningful response threshold for families or 
clinicians. Indeed, in clinic, a JIA ACR 30 response would often prompt further 
escalation of therapy. The parent/patient global assessments are often misunderstood, 
leading to inaccurate measurement. The ACR measure is not useful in clinical care 
because it requires blood test results and formal calculations of percent improvement 
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these reasons, it is not optimal for shared-decision making. A large, international 
collaboration is currently updating components of the core set to be more meaningful to 
providers and patients, but any format comparing multiple individual assessments to 
baseline will continue to be problematic (3).  
 
The Juvenile Arthritis Disease Activity Score (JADAS) (18), a continuous, composite 
measure of disease activity, has been proposed as an alternative. The JADAS conveys 
the level and change in disease activity. Further ongoing validation including defining 
meaningful levels of response and cut offs for disease activity levels is needed for use 
in clinical trials. Indeed, JADAS has been included in several positive registration trials 
as a secondary outcome and the JADAS cutoff for inactive disease could be used as an 
outcome, particularly in trials that incorporate treat-to-target design. The ACR 
Provisional Criteria for Clinical Inactive Disease (CID) (19) standardize the 
measurement of inactive disease and remission on and off medication, but require 
additional prospective validation. Although meaningful to patients and parents, the ACR 
CID definition does not incorporate the patient perception of disease status, which is a 
weakness. Strictly-applied CID criteria also describes a high level of response that may 
be difficult to attain during a registration trial (20). In addition, CID and JADAS Inactive 
Disease are not equivalent states, which could be a problem when using either outcome 
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PROs bring the impact of disease and treatment on families to clinical trials. Currently, 
registration trials incorporate generic PROs (e.g., Childhood Health Assessment 
Questionnaire [CHAQ] and Child Health Questionnaire [CHQ]) that are limited by 
substantial floor and ceiling effects and do not measure aspects of disease (e.g. fatigue) 
especially important to patients and families. Work is ongoing to validate the pediatric 
PROMIS® modules in JIA as part of the NIH funded PEPR consortium 
(https://www.peprconsortium.org/). The PROMIS computerized adaptive testing (CAT) 
forms, may be particularly useful. In addition to the PROMIS® measures, there are 
many other PROs available for use in children with JIA. PRO choice will vary based on 
the study population and the research questions of interest. Lastly, an Arthritis 
Foundation and CARRA sponsored externally led FDA Patient Focused Drug 
Development program was held August 2, 2018, to ascertain patient/family perspectives 
on critical domains to assess.  
 
Long-term medication safety studies and analysis 
Challenges also exist in evaluating long-term safety of new therapeutic agents following 
regulatory approval. Usage patterns in clinical practice are complex, with many children 
exposed to multiple medications. Data from the CARRA Registry indicates that 
approximately 40% of JIA patients treated with a biologic receive a second biologic 
within two years (unpublished). Registry data on JIA management in other countries 
reveals similar patterns (22, 23). Pharmacosurveillance approaches that do not 
adequately account for switching between therapeutic agents are therefore inadequate 
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Historically, medication safety has been studied in drug-specific prospective registries 
(phase IV studies) that enroll patients upon initiation of the new therapeutic agent. 
However, limited duration of follow up, small patient numbers, unnecessarily restrictive 
cohort inclusion criteria, no accounting for biologic switching, unreasonably high 
enrollment goals, and the absence of comparators has made meaningful assessment of 
phase IV study results impossible.  
 
More recent studies capture safety data using large prospective observational disease-
based registries (24, 25). Disease-based registries enroll patients with a specific 
disease irrespective of medication use. The most efficient approach is to include all 
patients newly starting study drug in a disease-based registry, irrespective of prior 
medication use or inclusion in a prior comparator cohort. Unfortunately, some studies 
have applied unnecessary restrictions, such as not allowing patients to switch from a 
comparator cohort to a study drug cohort during the course of follow-up. 
 
The uptake of new therapeutic agents to treat JIA in clinical practice is often slow, owing 
to the relative rarity of JIA and how well most patients respond to currently available 
biologic agents. Many of the patients who will be initiating a newly approved agent have 
already failed older available medications, and are waiting to start the new agent as 
soon as it is approved. Since this backlog of waiting patients will then rapidly diminish 
following agent approval, if companies are not poised to initiate enrollment for a phase 
IV safety study immediately at the time of drug approval, the opportunity to 
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lost. A uniform transparent regulatory approach to phase IV requirements including data 
collection in an approved disease-based registry would allow companies to anticipate 
their needs and initiate registry operations prior to new drug approval.  
 
Current regulatory mandates are based on specific patient numbers for phase IV 
studies with enrollment goals that can be unrealistically high. An alternative approach 
would study newly approved medications in the context of a disease-based registry for a 
pre-specified time period (e.g., 15 years), rather than for a pre-specified number of 
patients. The registries would provide safety data on all patients newly initiating the 
medication of interest and appropriate comparator patients during the same time period. 
This approach accounts for unpredictable utilization of new medications and does not 
penalize companies for slow uptake of new product, standardizes the rigor of safety 
data collection for all medications, and ensures new medications are studied for long 
enough and contemporaneously with comparators to meaningfully assess long-term 
safety.  
 
Unmet needs from the clinical perspective of parent/patient and providers 
Patients with JIA may face a lifetime of trying—and potentially failing—medications. 
Despite treatment advances, managing JIA is still trial and error. Medication delivery by 
injection is problematic and negatively impacts quality of life. Children who fail to 
achieve enduring remission may exhaust all currently approved medications. However, 
as the list of available medications grows, family and provider decision making becomes 
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compare when used for specific JIA categories?; (2) How often do patients need to be 
switched from one medication to another (same class or different class), and what is 
their outcome?; (3) Do long-term safety profiles differ by length of use, medication class 
and combination?; (4) Can clinical trial results be applied to JIA patients seen in the 
clinic?; and, (5) What predicts response and non-response for individual patients?  
 
To facilitate access to new therapies, it is imperative that clinical trial designs evolve to 
be more feasible, patient-centered and representative of the clinic population in terms of 
racial, ethnic, socioeconomic and disease characteristics. Increasingly, families and 
providers are demanding increased patient centeredness in trial design, especially in an 
environment with multiple treatment options already available. Clinical trials should be a 
source of hope and expanded knowledge, rather than a last resort for families with few 
options due to lack of insurance, failure of available medications, or residence in 
countries where biologics are not readily available. Novel patient-centered clinical trial 
designs are necessary to foster improved participation and timely trial completion. With 
a wide array of treatment options currently available and under development, patients 
and families want and need to know how medicines compare to one another, which 
work best for which JIA category and which populations of patients, which are safest in 
the long term, and ultimately which is best for their individual child. All patients and 
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Using validated PROs that are selected in collaboration with patients and parents 
ensures trial outcomes are meaningful to stakeholders as well as grounded in rigorous 
methodology. Incorporating PROs into study outcomes is essential to understand 
impactful changes in the patient experience. Efforts by OMERACT and the Arthritis 
Foundation confirm that 30% improvement in disease activity domains determined by 
clinicians is not sufficient for shared decision-making. Adopting a more robust patient-
centered approach to trial design and execution is a critical step forward. An externally-
led FDA Patient Focused Drug Development meeting sponsored by Arthritis Foundation 
and CARRA held in August 2018 is helping guide this process for JIA (26). Other 
international efforts are under way to promote the patient-centered perspective in 
setting outcomes and trial design, notably the OMERACT JIA group (27).  
The regulatory perspective  
Demonstration of a positive benefit/risk ratio based on evaluation of all available 
information acquired during drug development is required for regulatory approval of new 
medicines. Treatment advances for JIA exemplify the successful implementation of the 
Pediatric Research Equity Act (PREA) in the United States and Paediatric Regulation in 
the European Union (28). Most prior JIA authorization studies used a randomized 
withdrawal design showing significant differences between placebo and active treatment 
in the withdrawal phase in relatively small numbers of patients (average <150 total 
enrollment). Data from the larger, more comprehensive randomized controlled trials in 
adults, mostly with RA, enabled adoption of the JIA withdrawal design with smaller 
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Since a large volume of information exists from the development, authorization and 
clinical use of the first biologics for treating JIA (mainly anti-TNF agents), the FDA and 
EMA updated their guidance (29, 30) to officially include the statement that in certain 
situations formal confirmation of efficacy in children is not needed. Although 
pharmacokinetic (PK)/pharmacodynamic (PD) studies are always required in children to 
confirm dosing, a limited uncontrolled open-label study or other design developed for 
rare diseases can support extrapolation of efficacy from adult studies. This is only 
appropriate after careful assessment of available data and agreement between sponsor 
and the regulatory authorities on the specific extrapolation plan with input from 
independent disease experts and patient/families (2, 6). But for products targeting new 
pathways, opportunities to use extrapolation studies are much more limited, and use of 
placebo or an active comparator(s) is needed. However, the feasibility of parallel design 
studies in children with JIA is limited, due to the large number of products under 
development and the limited numbers of patients available and willing to participate. A 
randomized withdrawal design study requires less participants than a classical non-
inferiority study, but the example of the golimumab placebo-controlled withdrawal study 
highlighted limitations of this design in patients with relatively mild disease. Further 
development of innovative clinical trial methodologies facilitated by collaboration among 
patients and families, clinicians, researchers, industry and regulators will address 
changing needs, sparing pediatric patients from unnecessary trials while ensuring 
sufficient data to provide an evidence base for clinical decision-making. With this in 
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streamline drug development in line with current regulatory thinking and today’s social, 
medical, and marketing environment.   
 
During the April 2018 Denver stakeholders meeting, representatives of both the FDA 
and EMA encouraged pharmaceutical companies to utilize potential new trial designs, 
leverage Bayesian statistical analysis or extrapolation studies when possible, including 
modeling and simulation, and develop study plans with guidance from clinicians, 
researchers and patients/families to support the approval of new medicines for JIA. 
Guidelines including direction about what information is needed to support proposals is 
available (31, 32).  
 
The industry perspective 
The pharmaceutical industry wants to work in partnership with patients/families, 
clinicians, researchers, and regulators to design and deliver clinically meaningful and 
feasible trials. The April 2018 Denver stakeholders meeting demonstrated that 
collaborative and open dialogue between all stakeholders, especially regulators and 
industry, is desired and possible. However, reluctance still exists to ask regulators to 
update previously agreed upon decisions, even if it is to reflect current community 
needs and concerns. Additionally, informal interactions between industry and regulators 
may be helpful to facilitate new trial designs, assessing whether draft proposals are 
feasible and acceptable prior to formal submission. Even closer collaboration between 
the FDA and EMA, including alignment of drug development timelines, would promote 
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with a wide variety of expert opinion leaders and patients/families to garner diverse 
opinions and approaches, as well as with research networks, not only regarding design, 
but also operational and feasibility issues. Industry partners are committed to ensuring 
novel agents reach children in a timely fashion and recognize clinical trial 
methodologies being used no longer meet the needs of the community. Indeed, most 
presently agreed-upon PSPs and PIPs include pivotal phase III trial(s) in JIA (systemic 
JIA and polyarticular JIA) involving >300 patients each. With the increasing number of 
patients achieving satisfactory responses on currently available drugs, the ability of 
industry to meet these requirements is unlikely. Recent renegotiation of PSP/PIPs 
leading to smaller and shorter development plans indicates that all stakeholders respect 
the consequences of the current scenario on PSPs and PIPs.  
 
Potential solutions for the future 
Importantly, close collaboration between clinical trialists and methodologists across 
disciplines is resulting in increasing discussion of alternative study designs that are 
potentially superior to the placebo-withdrawal design for testing treatments in JIA and 
other pediatric rheumatic diseases, including uncontrolled open label, active comparator 
controlled, extrapolation, and others (33).  
 
Uncontrolled open label design 
Open-label pharmacokinetic and pharmacodynamic studies may be sufficient for 
regulatory approval in new therapeutic agents which directly target known disease 
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existing label for adult inflammatory arthritis (34). Previous PSP/PIPs for the TNF alpha 
inhibitor certolizumab, as well as the IL-6 receptor antagonist sarilumab, set precedence 
for this approach. Further scientific development of this concept by all stakeholders and 
approval by international regulators would be a key step in alleviating uncertainty about 
when this approach is acceptable. 
 
Given high rates of clinically inactive disease/remission in polyarticular JIA and systemic 
JIA using available biologics, a critical unmet medical need is treatment for patients with 
unsatisfactory response to current therapies. Therefore, agents targeting novel 
mechanisms of action with limited safety information might be appropriately evaluated in 
small open label trials with extensive PK and PD assessment including patients 
unresponsive to approved treatments and providing quicker access to needed 
treatments. This approach would also avoid ethical implications of using an 
experimental drug with or without placebo when proven alternatives are available (26). 
 
Active comparator controlled design 
Using an active comparator completely avoids exposing children to placebo while 
maintaining the advantages of a PRCT study. New molecules with Phase 3 data in adult 
inflammatory arthritis but never tested in children are candidates for this design in JIA. 
To ensure the burden of proof is not excessive, non-inferiority of the novel agent 
compared to the registered active comparator rather than superiority would be required. 
Careful consideration is needed to determine the acceptable relative efficacy leading to 
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produce more clinically meaningful results and be more acceptable and relevant to 
patients and families. Other issues with active comparator designs include 
establishment of safety in absence of a placebo arm, selecting an appropriate 
comparator as not all biologics are available in all countries, and the high cost of the 
comparator drugs, a problem companies could help one other resolve.  
 
Extrapolation  
Another approach to enable efficient and ethical evaluation of treatments is 
extrapolation, a complex concept that leverages all available information on the disease 
and medicine/class of medicines in question. The information is applied to the 
background of specific unmet needs, in order to identify which information can be 
inferred from testing in other populations, what information is missing, and how to 
mitigate remaining uncertainties. A Bayesian (adaptive) design can be part of this 
approach, where information from a relevant source (e.g. adult studies, non JIA 
pediatric studies, PK/PD studies, registries, and expert opinion) is used to inform the 
effect of study drug in JIA (31, 32, 35). Source information is augmented with trial 
observations in children with JIA and decisions about effectiveness are made based on 
the combined data. When the source information (e.g. estimated treatment effect in 
adults) is similar to what is observed in children, this design leads to increased power 
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Precision Medicine 
The most significant question asked frequently by patients/families and clinicians is, 
which drug is right for this child? To answer this critical question, clinical trials must 
move towards head-to-head studies of novel agents compared to established 
medications. Adaptive designs with small sample sizes, analysis of individual patient 




The April 2018 Denver meeting of stakeholders (industry, regulators, patients/families, 
investigators, clinicians and advocacy organizations) highlighted critical factors facing 
the timely approval of new medicines for JIA (Table 2). Collaboration among 
stakeholders with the shared goals of reducing barriers to regulatory approval including 
use of active comparator trials, extrapolation for authorization of “me-too” medicines, 
studying outcomes of importance to clinicians and patients, and ensuring adequate 
evaluation of long-term medication safety using disease-specific registries were key 
points discussed. In addition, speakers from both FDA and EMA discussed the use of 
alternative clinical trial designs including open-label and innovative approaches 
specifically adaptive and Bayesian methodologies, encouraging dialogue between 
industry, regulators, patients/families clinicians and investigators, including 
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In the presence of significant needs for new treatments for non-responders and answers 
to essential questions about individual drug selection, new and innovative changes are 
urgently needed to move forward the treatment of children with JIA and not just 
lengthen the list of registered medicinal products.  In addition, JIA patient numbers and 
the market environment cannot support the authorization of the large number of 
medications in development through multiple placebo-controlled trials running 
concurrently. Clinical trial methodology must and should change to fit the modern 
treatment landscape as well as the needs of the pediatric rheumatology community.  
Since this meeting was the initial step in discussing these issues regarding clinical trials 
and the role of registries, an important next step is being planned to engage the broader 
community of stakeholders in a large, public meeting to establish solutions through 
consensus on October 2, 2019. 
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Table 1. Estimated range of prevalent Enthesitis Related Arthritis (ERA) & Juvenile 
Psoriatic Arthritis (JPsA) patients eligible for study recruitment among European 
countries, the US, and Canada in 2025* 










Low End of 
Estimated 




High End of 
Estimated 






Prevalent ERA & 
JPsA Cases 
Estimated Number of 







 96,203,359 32.6 per 
100,000 
4.89 per 100,000 6.5 per 100,000 4,704-6,272 1,345-1,794 
US  66,829,693 44.7 per 
100,000 
6.71 per 100,000 8.9 per 100,000 4,481-5,975 1,282-1,709 
Canada  6,638473 44.7 per 
100,000  
6.71 per 100,000 8.9 per 100,000 445-593 127-170 
 
*All estimates for patients under age 16 
1 
United Nations, Department of Economic and Social Affairs, Population Division (2017). World 
Population Prospects: The 2017 Revision, custom data acquired via website. Age groupings available via 
query included 0-14 years of age. The population projection for those 15 years of age was calculated by 
obtaining 1/5
th
 of the 15-19 year old population figure.  
2 
European estimate obtained from Theirry et al. (2014)(36). US estimate obtained from Harrold et al. 
(2013)(37) 
3
Assumed that 15% of JIA prevalence is attributable to JPsA and ERA subtypes (Adib et al. 2008 (38), 
Weiss et al. 2012 (39), Sengler et al. 2015 (40)). 
4
Assumed that 20% of JIA prevalence is attributable to JPsA and ERA subtypes (Flato et al. 2009 (41)). 
5
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6
Europe includes: Belarus Bulgaria Czechia Hungary Poland Republic of Moldova Romania Slovakia 
Ukraine Channel Islands Denmark Estonia Finland Iceland Ireland Latvia Lithuania Norway Sweden 
United Kingdom Albania Bosnia and Herzegovina Croatia Greece Italy Malta Montenegro Portugal Serbia 
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Table 2: Summary of Different Stakeholder Perspectives Regarding Clinical Trials 
in Pediatric Rheumatology 




 Absence of head to head 
comparator studies to guide 
individual decision making  
 Randomized withdrawal and 
placebo designs not 
acceptable with marketed 
options available 
 Outcomes not meaningful to 
patients 
 Pragmatic and ethical 
considerations of placebo 
withdrawal design  
 Non-inferiority active 
comparator studies approved 
by regulators 
 Adaptive designs/open label 
for agents with similar 
mechanisms 
 New outcomes that are 
meaningful to patients and 
accepted by regulators 





 Insufficient input into study 
design/pediatric investigation 
plans 
 Trial designs and outcomes 
not relevant to clinical practice 
 Absence of head to head 
studies to guide medical 
decision making 
 Poor use of disease specific 
registries for safety 
surveillance 
 Unmet needs of non-
responders  
 Diverse investigator input to 
guide clinical trial design 
 Adaptive study designs with 
active comparators 
 Use of Bayesian 
methodology 
 Open label studies  
Industry  Prefers trial design accepted 
by regulators in the past 
 Difficulty enrolling/completing 
trials  
 Reluctance to propose 
 Clarity/transparency 
regarding expected 
regulatory response to novel 
study designs 
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extrapolation/adaptive 
design/open label studies 
because of uncertain 
regulatory response  
 Reluctance to request change 
in previously approved 
PSPs/PIPs even if plan not 
currently feasible 
trial design committees 
 Agreement and collaboration 
between FDA and EMA 
regarding requirements and 
timelines 
Regulators  Follow national laws and 
existing agency guidelines 
 Ensure equal treatment 
 Serve many stakeholders 
 Increased dialogue with all 
stakeholders – formal and 
colloquial 
 Align pediatric timelines 
between agencies 
 Encourage reassessment of 
existing PSPs and PIPs 
before implementation 
 
  
